{"ticker": {"uuid": "663cfaab-cbfb-4105-9f70-7bb48c25fbf7", "symbol": "BDSX", "name": "Biodesix\u00a0Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Diagnostics & Research"}, "articles": [{"title": "Biodesix Inc. (BDSX) Stock Price | Live Quotes & Charts | NASDAQ", "summary": "This page provides live stock quotes and charts for Biodesix Inc. (BDSX) on NASDAQ, showing its current price of $22.15 with no change. It indicates that there are currently no analyst ratings or earnings information available for the company. The page also features general tradi", "url": "https://timothysykes.com/quote/BDSX/", "source_name": "timothysykes.com", "published_at": "2026-07-09T23:10:47", "published_display": "09 Jul 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AIGH Capital Management LLC Buys Shares of 758,328 Biodesix, Inc. $BDSX", "summary": "AIGH Capital Management LLC has acquired 758,328 shares of Biodesix, Inc. (NASDAQ:BDSX) worth approximately $11.0 million, representing 7.5% of the company and 1.5% of AIGH's portfolio. Institutional investors collectively own 20.96% of Biodesix, with several hedge funds and asse", "url": "https://www.marketbeat.com/instant-alerts/filing-aigh-capital-management-llc-buys-shares-of-758328-biodesix-inc-bdsx-2026-07-09/", "source_name": "MarketBeat", "published_at": "2026-07-09T07:39:55", "published_display": "09 Jul 2026 07:39", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biodesix (BDSX) chair converts 1,361 RSUs and updates holdings", "summary": "John Patience, a director and chairman of Biodesix Inc. (BDSX), reported a routine equity compensation transaction where 1,361 restricted stock units (RSUs) converted into common shares on June 30, 2026, increasing his direct holdings to 25,383 shares. He also retains 2,721 RSUs,", "url": "https://www.stocktitan.net/sec-filings/BDSX/form-4-biodesix-inc-insider-trading-activity-ce3a9f0f0625.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:40:58", "published_display": "02 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biodesix, Inc.(NasdaqGM: BDSX) added to Russell Microcap Value Benchmark Index", "summary": "Biodesix, Inc. (NasdaqGM: BDSX) has been added to the Russell Microcap Value Benchmark Index. This inclusion highlights the company's position within the microcap market segment. The article also provides recent analyst ratings and company news, including earnings reports and cli", "url": "https://www.marketscreener.com/news/biodesix-inc-nasdaqgm-bdsx-added-to-russell-microcap-value-benchmark-index-ce7f5fdfd988f420", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T13:40:28", "published_display": "29 Jun 2026 13:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biodesix, Inc.(NasdaqGM: BDSX) added to Russell Microcap Growth Benchmark Index", "summary": "Biodesix, Inc. (NasdaqGM: BDSX), a diagnostic solutions company specializing in lung diagnostic testing and development services, has been added to the Russell Microcap Growth Benchmark Index. This inclusion highlights the company's growth potential and makes it eligible for a br", "url": "https://www.marketscreener.com/news/biodesix-inc-nasdaqgm-bdsx-added-to-russell-microcap-growth-benchmark-index-ce7f5fded089fe20", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T12:40:28", "published_display": "29 Jun 2026 12:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Biodesix, Inc. \u2013 NASDAQ:BDSX", "summary": "The article provides financial information for Biodesix, Inc. (NASDAQ: BDSX), specifically focusing on its enterprise value to revenue forward metric. It details where to find this data within the TradingView platform, alongside other financial overviews.", "url": "https://www.tradingview.com/symbols/NASDAQ-BDSX/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T23:09:54", "published_display": "27 Jun 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biodesix, Inc. Actuals & Estimates (NASDAQ:BDSX)", "summary": "This article provides an overview of Biodesix, Inc. (NASDAQ:BDSX) stock, including its current price, historical performance, analyst forecasts, and financial data. It highlights the company's recent earnings surprise, revenue figures, market capitalization, and upcoming earnings", "url": "https://www.tradingview.com/symbols/NASDAQ-BDSX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T00:39:24", "published_display": "27 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biodesix (BDSX) Stock Gets Fair Value Bump As Analysts Back Growth Path", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/biodesix-bdsx-stock-gets-fair-190728782.html", "source_name": "Simply Wall St.", "published_at": "2026-06-26T19:07:28+00:00", "published_display": "26 Jun 2026 19:07", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biodesix, Inc. Actuals & Estimates (BOATS:BDSX)", "summary": "This article provides an overview of Biodesix, Inc. (BDSX) including its financial actuals and estimates, stock forecast, historical prices, and upcoming earnings dates. It also details the company's recent earnings, revenue, net income, and EBITDA, along with information about i", "url": "https://www.tradingview.com/symbols/BOATS-BDSX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T15:09:37", "published_display": "26 Jun 2026 15:09", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Biodesix, Inc. \u2013 NASDAQ:BDSX", "summary": "The article provides financial information for Biodesix, Inc. (NASDAQ: BDSX), focusing on its forward price-to-earnings ratio. It is presented in the context of TradingView's market data offerings and includes various disclaimers regarding the data sources and copyright. The cont", "url": "https://www.tradingview.com/symbols/NASDAQ-BDSX/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T12:10:47", "published_display": "26 Jun 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BDSX Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a detailed forecast for Biodesix, Inc. (BDSX), including analyst price targets, historical stock performance, and financial data. It highlights the current stock price, volatility, market capitalization, and upcoming earnings report, offering a comprehensive", "url": "https://www.tradingview.com/symbols/NASDAQ-BDSX/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T08:10:23", "published_display": "26 Jun 2026 08:10", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roth Capital Initiates Biodesix at Buy With $32 Price Target", "summary": "Roth Capital has initiated coverage on Biodesix (BDSX) with a \"Buy\" rating and set a price target of $32.00, according to a report published on June 25, 2026. This positive outlook follows a previous \"Buy\" initiation by HC Wainwright on June 15, 2026, with a $26.00 price target. ", "url": "https://www.marketscreener.com/news/roth-capital-initiates-biodesix-at-buy-with-32-price-target-ce7f5fd8dc8eff23", "source_name": "marketscreener.com", "published_at": "2026-06-25T11:40:20", "published_display": "25 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biodesix | SCHEDULE 13G/A: Others", "summary": "This article provides a document link for Biodesix's SCHEDULE 13G/A filing, categorized under \"Others.\" The content directly links to the official filing, giving access to information about significant ownership stakes in the company.", "url": "https://www.moomoo.com/news/notice/307323511/biodesix-schedule-13g-a-others", "source_name": "Moomoo", "published_at": "2026-06-25T07:10:23", "published_display": "25 Jun 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biodesix Inc (BDSX) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Biodesix Inc (BDSX), focusing on its price momentum, support, and resistance levels. It details various technical indicators like MACD, RSI, and Moving Averages, which currently suggest a \"Buy\" signal for the stock. The article rates ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bdsx/technical", "source_name": "TradingKey", "published_at": "2026-06-22T18:10:18", "published_display": "22 Jun 2026 18:10", "sentiment": "positive", "sentiment_pct": 81, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biodesix (BDSX) Surges 10.5%: Is This an Indication of Further Gains?", "summary": "Biodesix (BDSX) shares increased by 10.5% due to strong investor optimism after Canaccord Genuity raised its price target from $22.00 to $27.00, maintaining a \"Buy\" rating. The company also made progress in its top-line growth, operational efficiency, and pipeline advancement in ", "url": "https://sg.finance.yahoo.com/news/biodesix-bdsx-surges-10-5-082700572.html", "source_name": "Market source", "published_at": "2026-06-19T12:27:00", "published_display": "19 Jun 2026 12:27", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Soleus discloses 525,241-share (5.1%) stake in Biodesix (BDSX)", "summary": "Soleus Capital Master Fund, L.P. and its affiliated entities have reported a 5.1% beneficial ownership stake in Biodesix (BDSX), totaling 525,241 shares. This disclosure was made via a Schedule 13G SEC filing, indicating a passive investment. The percentage is based on 10,355,809", "url": "https://www.stocktitan.net/sec-filings/BDSX/schedule-13g-biodesix-inc-passive-investment-disclosure-5-c0150c7d6455.html", "source_name": "Stock Titan", "published_at": "2026-06-18T20:47:07", "published_display": "18 Jun 2026 20:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Canaccord raises Biodesix stock price target to $27 on growth outlook", "summary": "Canaccord Genuity increased its price target for Biodesix Inc. (NASDAQ:BDSX) shares to $27 from $22, maintaining a Buy rating, citing increased cash flow estimates and competitive positioning. The company reported strong Q1 2026 revenue growth of 42% and raised full-year guidance", "url": "https://www.investing.com/news/analyst-ratings/canaccord-raises-biodesix-stock-price-target-to-27-on-growth-outlook-93CH-4749688", "source_name": "Investing.com", "published_at": "2026-06-18T11:39:50", "published_display": "18 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 81, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biodesix Inc (BDSX) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Biodesix Inc (BDSX) currently holds a financial score of 7.13, placing it in the weaker category within the Healthcare Providers & Services industry, despite average operating efficiency. The company recently reported a 42.30% year-over-year increase in quarterly revenue, reachin", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bdsx/financial-health", "source_name": "TradingKey", "published_at": "2026-06-17T20:39:50", "published_display": "17 Jun 2026 20:39", "sentiment": "positive", "sentiment_pct": 59, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biodesix Inc (BDSX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Biodesix Inc (BDSX) has an earnings forecast score of 8.40, placing it 18th in the Healthcare Providers & Services industry. Analysts have a consensus price target of $35.00, with a \"Buy\" rating from most surveyed analysts. The company's expected revenue for the next quarter is $", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bdsx/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T18:39:50", "published_display": "17 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biodesix Inc (BDSX) Valuation: PE, PB & Fair Value Analysis", "summary": "The article provides a valuation analysis of Biodesix Inc (BDSX), noting its current valuation score of 8.53, ranking 36 out of 76 in the Healthcare Providers & Services industry. It highlights the company's current P/E ratio of -4.24, which is significantly below its recent high", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bdsx/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-17T17:09:13", "published_display": "17 Jun 2026 17:09", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BDSX Technical Analysis & Stock Price Forecast", "summary": "The article provides a technical analysis of Biodesix Inc (BDSX), indicating a \"Strong Buy\" consensus based on various technical indicators. Key metrics like MACD, Moving Averages, and Support/Resistance levels are analyzed, with BDSX currently trading above its 200-day moving av", "url": "https://intellectia.ai/en/stock/BDSX/technical", "source_name": "Intellectia AI", "published_at": "2026-06-17T04:11:39", "published_display": "17 Jun 2026 04:11", "sentiment": "positive", "sentiment_pct": 82, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biodesix Inc (BDSX) Institutional Confidence", "summary": "Biodesix Inc (BDSX) has an institutional shareholding score of 3.00, placing it 56th out of 76 in the Healthcare Providers & Services industry. The latest institutional shareholding proportion is 29.99%, showing a 17.90% decrease quarter-over-quarter. James Simons is identified a", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bdsx/sentiment", "source_name": "TradingKey", "published_at": "2026-06-16T15:11:39", "published_display": "16 Jun 2026 15:11", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HC Wainwright Initiates Biodesix at Buy With $26 Price Target", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/hc-wainwright-initiates-biodesix-buy-102712985.html", "source_name": "MT Newswires", "published_at": "2026-06-15T10:27:12+00:00", "published_display": "15 Jun 2026 10:27", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BDSX Initiates Coverage On HC Wainwright & Co. -- Rating Set to Buy", "summary": "HC Wainwright & Co. has initiated coverage on Biodesix (BDSX) with a Buy rating and a price target of $26.00. GuruFocus assesses BDSX as undervalued by 28.3% with a GF Value\u2122 of $20.99, indicating a potential investment opportunity despite concerns regarding the company's financi", "url": "https://www.gurufocus.com/news/8915928/bdsx-initiates-coverage-on-hc-wainwright-co-rating-set-to-buy", "source_name": "GuruFocus", "published_at": "2026-06-15T10:39:05", "published_display": "15 Jun 2026 10:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Are Medical Stocks Lagging Biodesix (BDSX) This Year?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxOU3R2R2phc0l2WUctbFBrSkFjSlBzSnVEck5XZDdIM2xtUzJNZkxESlZfNldZOF9kSk8xODdLSEdPX2hXWFVzUm5rVUd4RWVPZk44RVp6MndRQ3pCcUxSc1FJeFNsUzFFQXB5Zkc2c09wZFZ1OWJtcTlhT2o5bm01Y1pDM19ZZEFnNmlMc3ZhN2U1TUxiOVJPSHIxOEdGblczVmhn?oc=5", "source_name": "Market source", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biodesix, Inc. (BDSX) reports Q1 loss, tops revenue estimates", "summary": "Biodesix, Inc. (BDSX) reported a narrower-than-expected loss in Q1, exceeding revenue estimates. The company posted a loss of $0.18 per share, which was better than the Zacks Consensus Estimate of a $0.23 loss per share. Revenue for the quarter reached $11.4 million, surpassing t", "url": "https://www.msn.com/en-us/money/other/biodesix-inc-bdsx-reports-q1-loss-tops-revenue-estimates/ar-AA22oqNK?ocid=BingNewsVerp", "source_name": "MSN", "published_at": "2026-06-11T14:08:47", "published_display": "11 Jun 2026 14:08", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zacks Industry Outlook Highlights BrightSpring Health Services, Biodesix and HealthEquity", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/zacks-industry-outlook-highlights-brightspring-111600958.html", "source_name": "Zacks", "published_at": "2026-06-09T11:16:00+00:00", "published_display": "09 Jun 2026 11:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BDSX - Biodesix Inc Stock Price and Quote", "summary": "This article provides a detailed stock overview for Biodesix Inc (BDSX), including its latest closing price, financial metrics, insider transactions, and recent news. It also lists analyst ratings and their corresponding price targets and actions for the company. The content high", "url": "https://finviz.com/stock?t=BDSX", "source_name": "Finviz", "published_at": "2026-06-05T11:09:05", "published_display": "05 Jun 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[EFFECT] BIODESIX INC SEC Filing", "summary": "This article reports on a recent SEC filing for Biodesix Inc. (NASDAQ: BDSX), specifically an EFFECT filing. The filing indicates an effectiveness date of May 29, 2026, for a Form S-3 (Shelf Registration Statement), with a CIK of 0001439725. The company's stock overview, market d", "url": "https://www.stocktitan.net/sec-filings/BDSX/effect-biodesix-inc-sec-filing-92d57be58112.html", "source_name": "Stock Titan", "published_at": "2026-06-01T10:39:48", "published_display": "01 Jun 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biodesix (NASDAQ: BDSX) registers resale of 375,000 shares", "summary": "Biodesix, Inc. (NASDAQ: BDSX) has filed a prospectus to register the resale of up to 375,000 shares of its common stock by the selling stockholder, Perceptive Credit Holdings IV, LP. These shares are issuable upon the exercise of specific warrant certificates, and the registratio", "url": "https://www.stocktitan.net/sec-filings/BDSX/424b3-biodesix-inc-prospectus-filed-pursuant-to-rule-424-b-3-b7fa30f35296.html", "source_name": "Stock Titan", "published_at": "2026-05-30T20:39:48", "published_display": "30 May 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts Believe Biodesix (BDSX) Could Rally 104.29%: Here's is How to Trade", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPNWQtNlJsZklLNzhodnlRaFFNdmV2WjF4M0xIMWJyeXVsbVo3ekl2dC1NTXNtUV9YZ1A1M1VQeE45Vm9IUHYzTGdna2dNc3JCYVJpT3U2eEFGMGwtc29EWnJjUDlKZDc0NjFiZHVOUEJzRVlRR1pnMGNORUp1cFRiczROS05Zb0Voc04wOGUzeTRaOXJSYTQ0czRJdmdwYlM5SVkyMw?oc=5", "source_name": "Market source", "published_at": "2026-05-25T07:00:00+00:00", "published_display": "25 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Canaccord Lifts PT on Biodesix (BDSX) on Raised Revenue Assumptions", "summary": "Canaccord has increased its price target for Biodesix (BDSX) from $20 to $22, maintaining a Buy rating, due to higher revenue assumptions and improved operating margins in its 10-year DCF model. This adjustment follows Biodesix's strong Q1 2026 results, which showed Diagnostic Te", "url": "https://www.insidermonkey.com/blog/canaccord-lifts-pt-on-biodesix-bdsx-on-raised-revenue-assumptions-1767528/?amp=1", "source_name": "Insider Monkey", "published_at": "2026-05-23T12:38:52", "published_display": "23 May 2026 12:38", "sentiment": "positive", "sentiment_pct": 85, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BDSX News | BIODESIX INC (NASDAQ:BDSX)", "summary": "This article provides a compilation of recent news and analysis related to Biodesix Inc (NASDAQ:BDSX). It includes past earnings reports, analyst expectations for stock rallies, and various other stock-related news where BDSX is mentioned alongside other companies. The current st", "url": "https://www.chartmill.com/stock/quote/BDSX/news", "source_name": "ChartMill", "published_at": "2026-05-23T05:40:31", "published_display": "23 May 2026 05:40", "sentiment": "positive", "sentiment_pct": 68, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biodesix (NASDAQ: BDSX) registers 375,000 shares for Perceptive resale", "summary": "Biodesix (NASDAQ: BDSX) has filed an S-3 registration statement to allow Perceptive Credit Holdings IV, LP to resell up to 375,000 shares of common stock. These shares are issuable upon the exercise of warrants granted under multiple amendments to a credit agreement. Biodesix wil", "url": "https://www.stocktitan.net/sec-filings/BDSX/s-3-biodesix-inc-shelf-registration-statement-255d020cd90e.html", "source_name": "Stock Titan", "published_at": "2026-05-22T03:33:03", "published_display": "22 May 2026 03:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biodesix to Participate in Upcoming Investor Conferences", "summary": "Biodesix, Inc. announced its leadership team will participate in three investor conferences: Craig-Hallum 23rd Annual Institutional Investor Conference, William Blair 46th Annual Growth Stock Conference, and TD Cowen Annual Tools & Diagnostics Revolution Conference. The presentat", "url": "https://www.caledonianrecord.com/biodesix-to-participate-in-upcoming-investor-conferences/article_5a7fe328-7808-53ec-aefc-24ceb35f05d9.html", "source_name": "Caledonian Record", "published_at": "2026-05-21T09:39:22", "published_display": "21 May 2026 09:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biodesix meets investors in Minneapolis, Chicago and Dana Point", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQeG1DbzRtTjR4SldhUnVMZjR1WkRCOTBPWFJ5Ri13dkpHT0FRa2xHdk1oLVlqY0dyNXgzdzlBS1dKZ2YwMFc5V3BHUHg2US1nNFlRaW1vekVMcUtvckl6c2VCUmNGbHREOVZHTFNzY3RoSno4LXUtUEdURkswSUt5N0ZaMmNHNTZ0ai01dVdDLV9tRktWQUJiZG9KbHpJYWM0?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biodesix plans May 4 Q1 results release, 4:30 p.m. ET webcast", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNOEN3YWJPSVdJYmVqY29QSUhIU3FwSkhHSkNzbjFZcXExdzFmWHNXOGNKMldhdEFKNEV0akFGOXBpQVdJa1hPX3dYWnJMcnR6UFVGVnhSTDFrandxYjFLeUt5MDI3Y0FPemRPZ3RyOUFuRENETnV2b1MtcmdtS3J2X0VRb2p5MW1rNjkxcWJMMmtwQmtSeGZCeDg3SzMyYmxRSjF3MURzSlNocHNWa2k5SHQxR0tRSndNZmJF?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Biodesix (BDSX) Stock Outpacing Its Medical Peers This Year?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNVk16M19BRmtOS09fZ1ZyY0h4SjJnaHg5enhQaEVMY0JYeERwNGg2LWVUaXhUNFpGUXBmdmFsU0ZEYmxCdnZpSHhxWHk5LS1HWUQ5UkpVaHRiQlM4bTFoX3hEQnZQUDZySEFrNmZJZ1RCTzdNUDJWcG9hc3FuR1NyYWo1SWk1QmlBODA1YzA5UFpsb1JGbXE2X3ZDQVhySGdrR2FYVg?oc=5", "source_name": "Market source", "published_at": "2026-03-19T07:00:00+00:00", "published_display": "19 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Biodesix (BDSX) Investment Story Is Shifting After Guidance And New US$30 Target", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxNdERySnNDalNMY2RhYXJHMnlrSFczMzk1NmNjOGFhSnRIYmptZ0VQU3VpQ3huSE1SRjItQjY2eURUYTlLdWFscEJONmxQR2dFZlh1SWtHSU9WWmJuRmRrSGdJQ1NCVXRZZnVxMTM3MXRKT084WEpJVkEzOUZYcTVHUVZrcWhMWWFGS3lISDVR?oc=5", "source_name": "Market source", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Investors Still Aren't Entirely Convinced By Biodesix, Inc.'s (NASDAQ:BDSX) Revenues Despite 26% Price Jump", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-14T08:00:00+00:00", "published_display": "14 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biodesix Stock Rebounds on Strategic Plans for Market Expansion", "summary": "", "url": "https://news.google.com/rss/articles/CBMid0FVX3lxTE9zR2VrQVlUOXlrSWpsZ0pWNzk2Z3dHZGtyaHVrR3Rfa1dJZEtmeXpFY1NQZzU4NmFLUWR2c0FhTlV0OERWUWNFZHI4dDFRd052eEx3Zm5IVkx2LWNDOG8zRWVsZVFLcWRGVFk4MjRhem9DckJsVTlr?oc=5", "source_name": "timothysykes.com", "published_at": "2026-01-12T08:00:00+00:00", "published_display": "12 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biodesix, Inc. Reports Estimated Q4 2025 Revenue of $28.8 Million, Achieving 41% Growth and Full-Year Revenue of $88.5 Million, Up 24%", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgJBVV95cUxQM20wMXJiQlZZdUdhT3pKRVZfYVI0Tnk3ajdMd2lEeW9XXzBfcXRqZlBvYVhrOGd2dXlZRHhBVlYyMWM1a0xoTW5QcnRKTEpIZzVVb0ZURk0takdVd3NxOUhKX3F3aEpWU2hna1VqWTZvb1RITk13WFdRU2NST1VLSjdnS0hoQTR0N0hXbGlQOE52SGk0c1ZTSDI2cXdXSV9hcnE1QWV6aC03Wmd4SnVKTjZURDNFNDZsS0ROSDlqX2wzNU5NVDhVZjVJMEhDQ3FaQ0cyUjE4czgyTlBlSDFJekozamsxSTRqb0NwVjRlTUZFTDRpeF9QbmZtWjc2ajdNbmstMEl5bVhJd196aEE?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-01-12T08:00:00+00:00", "published_display": "12 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lung cancer testing helps Biodesix lift Q4 2025 revenue by 41%", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQaTBCd0F6RnA5UnU5a2lJVURRN3dxNkVHRzg4VFkwTGE3TWRQYkFVeWJIZmZyWEFObkdOTk1ad1Zyckx1aWtuWHVUbjNKeVRZVW9fWEFqbTQxS2Zuekc1RGxNbkl3Tm41X3pXRkhFYVVRZDFOU3VUWGUyS3RxOWQ3aUF5d19rZFdZMmdib0pPek83ZVBTLTZCWFFIMEdFcVRwdGFKdHZraHRlS09WWmphTkhoeDVIdERpeXdR?oc=5", "source_name": "Stock Titan", "published_at": "2026-01-12T08:00:00+00:00", "published_display": "12 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biodesix Delivers 21% Revenue Growth: Inside Their Path to Profitability and Sales Team Transformation", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOeDJTZFBRd2EtUURNMkpxSGwzTWpNMDJfSmU4Ykh2a0JfRFhCOVZGdEsycmJyV0FLUFlPQVVxTnhxZlBDX3RNUmNOVEhHT2d0RHFIajU2LW5yZUFYdFJ4dEstV2s4LUtON0w4LThBX0paV1NZNVFCUDNlbWZWVUtKMThIUjkzT3BldEVrblBrWmdCbFNXc3d3cmQzT25sOHBLNWRrbjZUZw?oc=5", "source_name": "Stock Titan", "published_at": "2025-05-13T07:00:00+00:00", "published_display": "13 May 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BIODESIX (BDSX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE1odGJmdTl6MGd4aE5lb3RGVnBWdlBrSmdKZ1JGNkNnaUhELXpKVTgyVEhjVndwdm9NckJ6TEI5TEN6N1luNGljMHZURWN3OG00Rll3?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:33:21+00:00", "published_display": "25 Apr 2025 00:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Biodesix Inc. (BDSX) Stock Price | Live Quotes & Charts | NASDAQ", "summary": "This page provides live stock quotes and charts for Biodesix Inc. (BDSX) on NASDAQ, showing its current price of $22.15 with no change. It indicates that there are currently no analyst ratings or earnings information available for the company. The page also features general tradi", "url": "https://timothysykes.com/quote/BDSX/", "source_name": "timothysykes.com", "published_at": "2026-07-09T23:10:47", "published_display": "09 Jul 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AIGH Capital Management LLC Buys Shares of 758,328 Biodesix, Inc. $BDSX", "summary": "AIGH Capital Management LLC has acquired 758,328 shares of Biodesix, Inc. (NASDAQ:BDSX) worth approximately $11.0 million, representing 7.5% of the company and 1.5% of AIGH's portfolio. Institutional investors collectively own 20.96% of Biodesix, with several hedge funds and asse", "url": "https://www.marketbeat.com/instant-alerts/filing-aigh-capital-management-llc-buys-shares-of-758328-biodesix-inc-bdsx-2026-07-09/", "source_name": "MarketBeat", "published_at": "2026-07-09T07:39:55", "published_display": "09 Jul 2026 07:39", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biodesix (BDSX) chair converts 1,361 RSUs and updates holdings", "summary": "John Patience, a director and chairman of Biodesix Inc. (BDSX), reported a routine equity compensation transaction where 1,361 restricted stock units (RSUs) converted into common shares on June 30, 2026, increasing his direct holdings to 25,383 shares. He also retains 2,721 RSUs,", "url": "https://www.stocktitan.net/sec-filings/BDSX/form-4-biodesix-inc-insider-trading-activity-ce3a9f0f0625.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:40:58", "published_display": "02 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biodesix, Inc.(NasdaqGM: BDSX) added to Russell Microcap Value Benchmark Index", "summary": "Biodesix, Inc. (NasdaqGM: BDSX) has been added to the Russell Microcap Value Benchmark Index. This inclusion highlights the company's position within the microcap market segment. The article also provides recent analyst ratings and company news, including earnings reports and cli", "url": "https://www.marketscreener.com/news/biodesix-inc-nasdaqgm-bdsx-added-to-russell-microcap-value-benchmark-index-ce7f5fdfd988f420", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T13:40:28", "published_display": "29 Jun 2026 13:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biodesix, Inc.(NasdaqGM: BDSX) added to Russell Microcap Growth Benchmark Index", "summary": "Biodesix, Inc. (NasdaqGM: BDSX), a diagnostic solutions company specializing in lung diagnostic testing and development services, has been added to the Russell Microcap Growth Benchmark Index. This inclusion highlights the company's growth potential and makes it eligible for a br", "url": "https://www.marketscreener.com/news/biodesix-inc-nasdaqgm-bdsx-added-to-russell-microcap-growth-benchmark-index-ce7f5fded089fe20", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T12:40:28", "published_display": "29 Jun 2026 12:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Biodesix, Inc. \u2013 NASDAQ:BDSX", "summary": "The article provides financial information for Biodesix, Inc. (NASDAQ: BDSX), specifically focusing on its enterprise value to revenue forward metric. It details where to find this data within the TradingView platform, alongside other financial overviews.", "url": "https://www.tradingview.com/symbols/NASDAQ-BDSX/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T23:09:54", "published_display": "27 Jun 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biodesix, Inc. Actuals & Estimates (NASDAQ:BDSX)", "summary": "This article provides an overview of Biodesix, Inc. (NASDAQ:BDSX) stock, including its current price, historical performance, analyst forecasts, and financial data. It highlights the company's recent earnings surprise, revenue figures, market capitalization, and upcoming earnings", "url": "https://www.tradingview.com/symbols/NASDAQ-BDSX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T00:39:24", "published_display": "27 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biodesix (BDSX) Stock Gets Fair Value Bump As Analysts Back Growth Path", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/biodesix-bdsx-stock-gets-fair-190728782.html", "source_name": "Simply Wall St.", "published_at": "2026-06-26T19:07:28+00:00", "published_display": "26 Jun 2026 19:07", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biodesix, Inc. Actuals & Estimates (BOATS:BDSX)", "summary": "This article provides an overview of Biodesix, Inc. (BDSX) including its financial actuals and estimates, stock forecast, historical prices, and upcoming earnings dates. It also details the company's recent earnings, revenue, net income, and EBITDA, along with information about i", "url": "https://www.tradingview.com/symbols/BOATS-BDSX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T15:09:37", "published_display": "26 Jun 2026 15:09", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Biodesix, Inc. \u2013 NASDAQ:BDSX", "summary": "The article provides financial information for Biodesix, Inc. (NASDAQ: BDSX), focusing on its forward price-to-earnings ratio. It is presented in the context of TradingView's market data offerings and includes various disclaimers regarding the data sources and copyright. The cont", "url": "https://www.tradingview.com/symbols/NASDAQ-BDSX/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T12:10:47", "published_display": "26 Jun 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BDSX Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a detailed forecast for Biodesix, Inc. (BDSX), including analyst price targets, historical stock performance, and financial data. It highlights the current stock price, volatility, market capitalization, and upcoming earnings report, offering a comprehensive", "url": "https://www.tradingview.com/symbols/NASDAQ-BDSX/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T08:10:23", "published_display": "26 Jun 2026 08:10", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roth Capital Initiates Biodesix at Buy With $32 Price Target", "summary": "Roth Capital has initiated coverage on Biodesix (BDSX) with a \"Buy\" rating and set a price target of $32.00, according to a report published on June 25, 2026. This positive outlook follows a previous \"Buy\" initiation by HC Wainwright on June 15, 2026, with a $26.00 price target. ", "url": "https://www.marketscreener.com/news/roth-capital-initiates-biodesix-at-buy-with-32-price-target-ce7f5fd8dc8eff23", "source_name": "marketscreener.com", "published_at": "2026-06-25T11:40:20", "published_display": "25 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biodesix | SCHEDULE 13G/A: Others", "summary": "This article provides a document link for Biodesix's SCHEDULE 13G/A filing, categorized under \"Others.\" The content directly links to the official filing, giving access to information about significant ownership stakes in the company.", "url": "https://www.moomoo.com/news/notice/307323511/biodesix-schedule-13g-a-others", "source_name": "Moomoo", "published_at": "2026-06-25T07:10:23", "published_display": "25 Jun 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biodesix Inc (BDSX) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Biodesix Inc (BDSX), focusing on its price momentum, support, and resistance levels. It details various technical indicators like MACD, RSI, and Moving Averages, which currently suggest a \"Buy\" signal for the stock. The article rates ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bdsx/technical", "source_name": "TradingKey", "published_at": "2026-06-22T18:10:18", "published_display": "22 Jun 2026 18:10", "sentiment": "positive", "sentiment_pct": 81, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biodesix (BDSX) Surges 10.5%: Is This an Indication of Further Gains?", "summary": "Biodesix (BDSX) shares increased by 10.5% due to strong investor optimism after Canaccord Genuity raised its price target from $22.00 to $27.00, maintaining a \"Buy\" rating. The company also made progress in its top-line growth, operational efficiency, and pipeline advancement in ", "url": "https://sg.finance.yahoo.com/news/biodesix-bdsx-surges-10-5-082700572.html", "source_name": "Market source", "published_at": "2026-06-19T12:27:00", "published_display": "19 Jun 2026 12:27", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Soleus discloses 525,241-share (5.1%) stake in Biodesix (BDSX)", "summary": "Soleus Capital Master Fund, L.P. and its affiliated entities have reported a 5.1% beneficial ownership stake in Biodesix (BDSX), totaling 525,241 shares. This disclosure was made via a Schedule 13G SEC filing, indicating a passive investment. The percentage is based on 10,355,809", "url": "https://www.stocktitan.net/sec-filings/BDSX/schedule-13g-biodesix-inc-passive-investment-disclosure-5-c0150c7d6455.html", "source_name": "Stock Titan", "published_at": "2026-06-18T20:47:07", "published_display": "18 Jun 2026 20:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Canaccord raises Biodesix stock price target to $27 on growth outlook", "summary": "Canaccord Genuity increased its price target for Biodesix Inc. (NASDAQ:BDSX) shares to $27 from $22, maintaining a Buy rating, citing increased cash flow estimates and competitive positioning. The company reported strong Q1 2026 revenue growth of 42% and raised full-year guidance", "url": "https://www.investing.com/news/analyst-ratings/canaccord-raises-biodesix-stock-price-target-to-27-on-growth-outlook-93CH-4749688", "source_name": "Investing.com", "published_at": "2026-06-18T11:39:50", "published_display": "18 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 81, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biodesix Inc (BDSX) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Biodesix Inc (BDSX) currently holds a financial score of 7.13, placing it in the weaker category within the Healthcare Providers & Services industry, despite average operating efficiency. The company recently reported a 42.30% year-over-year increase in quarterly revenue, reachin", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bdsx/financial-health", "source_name": "TradingKey", "published_at": "2026-06-17T20:39:50", "published_display": "17 Jun 2026 20:39", "sentiment": "positive", "sentiment_pct": 59, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biodesix Inc (BDSX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Biodesix Inc (BDSX) has an earnings forecast score of 8.40, placing it 18th in the Healthcare Providers & Services industry. Analysts have a consensus price target of $35.00, with a \"Buy\" rating from most surveyed analysts. The company's expected revenue for the next quarter is $", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bdsx/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T18:39:50", "published_display": "17 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biodesix Inc (BDSX) Valuation: PE, PB & Fair Value Analysis", "summary": "The article provides a valuation analysis of Biodesix Inc (BDSX), noting its current valuation score of 8.53, ranking 36 out of 76 in the Healthcare Providers & Services industry. It highlights the company's current P/E ratio of -4.24, which is significantly below its recent high", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bdsx/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-17T17:09:13", "published_display": "17 Jun 2026 17:09", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BDSX Technical Analysis & Stock Price Forecast", "summary": "The article provides a technical analysis of Biodesix Inc (BDSX), indicating a \"Strong Buy\" consensus based on various technical indicators. Key metrics like MACD, Moving Averages, and Support/Resistance levels are analyzed, with BDSX currently trading above its 200-day moving av", "url": "https://intellectia.ai/en/stock/BDSX/technical", "source_name": "Intellectia AI", "published_at": "2026-06-17T04:11:39", "published_display": "17 Jun 2026 04:11", "sentiment": "positive", "sentiment_pct": 82, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biodesix Inc (BDSX) Institutional Confidence", "summary": "Biodesix Inc (BDSX) has an institutional shareholding score of 3.00, placing it 56th out of 76 in the Healthcare Providers & Services industry. The latest institutional shareholding proportion is 29.99%, showing a 17.90% decrease quarter-over-quarter. James Simons is identified a", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bdsx/sentiment", "source_name": "TradingKey", "published_at": "2026-06-16T15:11:39", "published_display": "16 Jun 2026 15:11", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HC Wainwright Initiates Biodesix at Buy With $26 Price Target", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/hc-wainwright-initiates-biodesix-buy-102712985.html", "source_name": "MT Newswires", "published_at": "2026-06-15T10:27:12+00:00", "published_display": "15 Jun 2026 10:27", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BDSX Initiates Coverage On HC Wainwright & Co. -- Rating Set to Buy", "summary": "HC Wainwright & Co. has initiated coverage on Biodesix (BDSX) with a Buy rating and a price target of $26.00. GuruFocus assesses BDSX as undervalued by 28.3% with a GF Value\u2122 of $20.99, indicating a potential investment opportunity despite concerns regarding the company's financi", "url": "https://www.gurufocus.com/news/8915928/bdsx-initiates-coverage-on-hc-wainwright-co-rating-set-to-buy", "source_name": "GuruFocus", "published_at": "2026-06-15T10:39:05", "published_display": "15 Jun 2026 10:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Are Medical Stocks Lagging Biodesix (BDSX) This Year?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxOU3R2R2phc0l2WUctbFBrSkFjSlBzSnVEck5XZDdIM2xtUzJNZkxESlZfNldZOF9kSk8xODdLSEdPX2hXWFVzUm5rVUd4RWVPZk44RVp6MndRQ3pCcUxSc1FJeFNsUzFFQXB5Zkc2c09wZFZ1OWJtcTlhT2o5bm01Y1pDM19ZZEFnNmlMc3ZhN2U1TUxiOVJPSHIxOEdGblczVmhn?oc=5", "source_name": "Market source", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biodesix, Inc. (BDSX) reports Q1 loss, tops revenue estimates", "summary": "Biodesix, Inc. (BDSX) reported a narrower-than-expected loss in Q1, exceeding revenue estimates. The company posted a loss of $0.18 per share, which was better than the Zacks Consensus Estimate of a $0.23 loss per share. Revenue for the quarter reached $11.4 million, surpassing t", "url": "https://www.msn.com/en-us/money/other/biodesix-inc-bdsx-reports-q1-loss-tops-revenue-estimates/ar-AA22oqNK?ocid=BingNewsVerp", "source_name": "MSN", "published_at": "2026-06-11T14:08:47", "published_display": "11 Jun 2026 14:08", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zacks Industry Outlook Highlights BrightSpring Health Services, Biodesix and HealthEquity", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/zacks-industry-outlook-highlights-brightspring-111600958.html", "source_name": "Zacks", "published_at": "2026-06-09T11:16:00+00:00", "published_display": "09 Jun 2026 11:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BDSX - Biodesix Inc Stock Price and Quote", "summary": "This article provides a detailed stock overview for Biodesix Inc (BDSX), including its latest closing price, financial metrics, insider transactions, and recent news. It also lists analyst ratings and their corresponding price targets and actions for the company. The content high", "url": "https://finviz.com/stock?t=BDSX", "source_name": "Finviz", "published_at": "2026-06-05T11:09:05", "published_display": "05 Jun 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[EFFECT] BIODESIX INC SEC Filing", "summary": "This article reports on a recent SEC filing for Biodesix Inc. (NASDAQ: BDSX), specifically an EFFECT filing. The filing indicates an effectiveness date of May 29, 2026, for a Form S-3 (Shelf Registration Statement), with a CIK of 0001439725. The company's stock overview, market d", "url": "https://www.stocktitan.net/sec-filings/BDSX/effect-biodesix-inc-sec-filing-92d57be58112.html", "source_name": "Stock Titan", "published_at": "2026-06-01T10:39:48", "published_display": "01 Jun 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biodesix (NASDAQ: BDSX) registers resale of 375,000 shares", "summary": "Biodesix, Inc. (NASDAQ: BDSX) has filed a prospectus to register the resale of up to 375,000 shares of its common stock by the selling stockholder, Perceptive Credit Holdings IV, LP. These shares are issuable upon the exercise of specific warrant certificates, and the registratio", "url": "https://www.stocktitan.net/sec-filings/BDSX/424b3-biodesix-inc-prospectus-filed-pursuant-to-rule-424-b-3-b7fa30f35296.html", "source_name": "Stock Titan", "published_at": "2026-05-30T20:39:48", "published_display": "30 May 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts Believe Biodesix (BDSX) Could Rally 104.29%: Here's is How to Trade", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPNWQtNlJsZklLNzhodnlRaFFNdmV2WjF4M0xIMWJyeXVsbVo3ekl2dC1NTXNtUV9YZ1A1M1VQeE45Vm9IUHYzTGdna2dNc3JCYVJpT3U2eEFGMGwtc29EWnJjUDlKZDc0NjFiZHVOUEJzRVlRR1pnMGNORUp1cFRiczROS05Zb0Voc04wOGUzeTRaOXJSYTQ0czRJdmdwYlM5SVkyMw?oc=5", "source_name": "Market source", "published_at": "2026-05-25T07:00:00+00:00", "published_display": "25 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Canaccord Lifts PT on Biodesix (BDSX) on Raised Revenue Assumptions", "summary": "Canaccord has increased its price target for Biodesix (BDSX) from $20 to $22, maintaining a Buy rating, due to higher revenue assumptions and improved operating margins in its 10-year DCF model. This adjustment follows Biodesix's strong Q1 2026 results, which showed Diagnostic Te", "url": "https://www.insidermonkey.com/blog/canaccord-lifts-pt-on-biodesix-bdsx-on-raised-revenue-assumptions-1767528/?amp=1", "source_name": "Insider Monkey", "published_at": "2026-05-23T12:38:52", "published_display": "23 May 2026 12:38", "sentiment": "positive", "sentiment_pct": 85, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BDSX News | BIODESIX INC (NASDAQ:BDSX)", "summary": "This article provides a compilation of recent news and analysis related to Biodesix Inc (NASDAQ:BDSX). It includes past earnings reports, analyst expectations for stock rallies, and various other stock-related news where BDSX is mentioned alongside other companies. The current st", "url": "https://www.chartmill.com/stock/quote/BDSX/news", "source_name": "ChartMill", "published_at": "2026-05-23T05:40:31", "published_display": "23 May 2026 05:40", "sentiment": "positive", "sentiment_pct": 68, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biodesix (NASDAQ: BDSX) registers 375,000 shares for Perceptive resale", "summary": "Biodesix (NASDAQ: BDSX) has filed an S-3 registration statement to allow Perceptive Credit Holdings IV, LP to resell up to 375,000 shares of common stock. These shares are issuable upon the exercise of warrants granted under multiple amendments to a credit agreement. Biodesix wil", "url": "https://www.stocktitan.net/sec-filings/BDSX/s-3-biodesix-inc-shelf-registration-statement-255d020cd90e.html", "source_name": "Stock Titan", "published_at": "2026-05-22T03:33:03", "published_display": "22 May 2026 03:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biodesix to Participate in Upcoming Investor Conferences", "summary": "Biodesix, Inc. announced its leadership team will participate in three investor conferences: Craig-Hallum 23rd Annual Institutional Investor Conference, William Blair 46th Annual Growth Stock Conference, and TD Cowen Annual Tools & Diagnostics Revolution Conference. The presentat", "url": "https://www.caledonianrecord.com/biodesix-to-participate-in-upcoming-investor-conferences/article_5a7fe328-7808-53ec-aefc-24ceb35f05d9.html", "source_name": "Caledonian Record", "published_at": "2026-05-21T09:39:22", "published_display": "21 May 2026 09:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biodesix meets investors in Minneapolis, Chicago and Dana Point", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQeG1DbzRtTjR4SldhUnVMZjR1WkRCOTBPWFJ5Ri13dkpHT0FRa2xHdk1oLVlqY0dyNXgzdzlBS1dKZ2YwMFc5V3BHUHg2US1nNFlRaW1vekVMcUtvckl6c2VCUmNGbHREOVZHTFNzY3RoSno4LXUtUEdURkswSUt5N0ZaMmNHNTZ0ai01dVdDLV9tRktWQUJiZG9KbHpJYWM0?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biodesix plans May 4 Q1 results release, 4:30 p.m. ET webcast", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNOEN3YWJPSVdJYmVqY29QSUhIU3FwSkhHSkNzbjFZcXExdzFmWHNXOGNKMldhdEFKNEV0akFGOXBpQVdJa1hPX3dYWnJMcnR6UFVGVnhSTDFrandxYjFLeUt5MDI3Y0FPemRPZ3RyOUFuRENETnV2b1MtcmdtS3J2X0VRb2p5MW1rNjkxcWJMMmtwQmtSeGZCeDg3SzMyYmxRSjF3MURzSlNocHNWa2k5SHQxR0tRSndNZmJF?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Biodesix (BDSX) Stock Outpacing Its Medical Peers This Year?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNVk16M19BRmtOS09fZ1ZyY0h4SjJnaHg5enhQaEVMY0JYeERwNGg2LWVUaXhUNFpGUXBmdmFsU0ZEYmxCdnZpSHhxWHk5LS1HWUQ5UkpVaHRiQlM4bTFoX3hEQnZQUDZySEFrNmZJZ1RCTzdNUDJWcG9hc3FuR1NyYWo1SWk1QmlBODA1YzA5UFpsb1JGbXE2X3ZDQVhySGdrR2FYVg?oc=5", "source_name": "Market source", "published_at": "2026-03-19T07:00:00+00:00", "published_display": "19 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Biodesix (BDSX) Investment Story Is Shifting After Guidance And New US$30 Target", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxNdERySnNDalNMY2RhYXJHMnlrSFczMzk1NmNjOGFhSnRIYmptZ0VQU3VpQ3huSE1SRjItQjY2eURUYTlLdWFscEJONmxQR2dFZlh1SWtHSU9WWmJuRmRrSGdJQ1NCVXRZZnVxMTM3MXRKT084WEpJVkEzOUZYcTVHUVZrcWhMWWFGS3lISDVR?oc=5", "source_name": "Market source", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Investors Still Aren't Entirely Convinced By Biodesix, Inc.'s (NASDAQ:BDSX) Revenues Despite 26% Price Jump", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-14T08:00:00+00:00", "published_display": "14 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biodesix Stock Rebounds on Strategic Plans for Market Expansion", "summary": "", "url": "https://news.google.com/rss/articles/CBMid0FVX3lxTE9zR2VrQVlUOXlrSWpsZ0pWNzk2Z3dHZGtyaHVrR3Rfa1dJZEtmeXpFY1NQZzU4NmFLUWR2c0FhTlV0OERWUWNFZHI4dDFRd052eEx3Zm5IVkx2LWNDOG8zRWVsZVFLcWRGVFk4MjRhem9DckJsVTlr?oc=5", "source_name": "timothysykes.com", "published_at": "2026-01-12T08:00:00+00:00", "published_display": "12 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biodesix, Inc. Reports Estimated Q4 2025 Revenue of $28.8 Million, Achieving 41% Growth and Full-Year Revenue of $88.5 Million, Up 24%", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgJBVV95cUxQM20wMXJiQlZZdUdhT3pKRVZfYVI0Tnk3ajdMd2lEeW9XXzBfcXRqZlBvYVhrOGd2dXlZRHhBVlYyMWM1a0xoTW5QcnRKTEpIZzVVb0ZURk0takdVd3NxOUhKX3F3aEpWU2hna1VqWTZvb1RITk13WFdRU2NST1VLSjdnS0hoQTR0N0hXbGlQOE52SGk0c1ZTSDI2cXdXSV9hcnE1QWV6aC03Wmd4SnVKTjZURDNFNDZsS0ROSDlqX2wzNU5NVDhVZjVJMEhDQ3FaQ0cyUjE4czgyTlBlSDFJekozamsxSTRqb0NwVjRlTUZFTDRpeF9QbmZtWjc2ajdNbmstMEl5bVhJd196aEE?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-01-12T08:00:00+00:00", "published_display": "12 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lung cancer testing helps Biodesix lift Q4 2025 revenue by 41%", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQaTBCd0F6RnA5UnU5a2lJVURRN3dxNkVHRzg4VFkwTGE3TWRQYkFVeWJIZmZyWEFObkdOTk1ad1Zyckx1aWtuWHVUbjNKeVRZVW9fWEFqbTQxS2Zuekc1RGxNbkl3Tm41X3pXRkhFYVVRZDFOU3VUWGUyS3RxOWQ3aUF5d19rZFdZMmdib0pPek83ZVBTLTZCWFFIMEdFcVRwdGFKdHZraHRlS09WWmphTkhoeDVIdERpeXdR?oc=5", "source_name": "Stock Titan", "published_at": "2026-01-12T08:00:00+00:00", "published_display": "12 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biodesix Delivers 21% Revenue Growth: Inside Their Path to Profitability and Sales Team Transformation", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOeDJTZFBRd2EtUURNMkpxSGwzTWpNMDJfSmU4Ykh2a0JfRFhCOVZGdEsycmJyV0FLUFlPQVVxTnhxZlBDX3RNUmNOVEhHT2d0RHFIajU2LW5yZUFYdFJ4dEstV2s4LUtON0w4LThBX0paV1NZNVFCUDNlbWZWVUtKMThIUjkzT3BldEVrblBrWmdCbFNXc3d3cmQzT25sOHBLNWRrbjZUZw?oc=5", "source_name": "Stock Titan", "published_at": "2025-05-13T07:00:00+00:00", "published_display": "13 May 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BIODESIX (BDSX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE1odGJmdTl6MGd4aE5lb3RGVnBWdlBrSmdKZ1JGNkNnaUhELXpKVTgyVEhjVndwdm9NckJ6TEI5TEN6N1luNGljMHZURWN3OG00Rll3?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:33:21+00:00", "published_display": "25 Apr 2025 00:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 97, "total_relevant": 45, "sentiment_summary": {"positive": 23, "negative": 0, "neutral": 22, "score": 61, "total": 45, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 72, "events": [{"event": "general", "label": "Market update", "weight": 8.8, "count": 16}, {"event": "earnings", "label": "Earnings", "weight": 8.25, "count": 15}, {"event": "analyst", "label": "Analyst action", "weight": 3.3, "count": 6}, {"event": "guidance", "label": "Guidance", "weight": 2.55, "count": 4}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "macro", "label": "Macro sensitivity", "weight": 0.55, "count": 1}], "positive_events": 23, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 21.42, "latest_week": "2026-07-10", "one_week_move": -2.6, "four_week_move": 42.2, "twelve_week_move": 63.0, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.757439, "market_dynamics_buy_signal": false, "relative_strength": 67.958838, "fair_value_gap": 0.3, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 50.0, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-2.6% over one week, +42.2% over four weeks, trend active, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 68, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 10}, {"label": "TradingView", "count": 5}, {"label": "TradingKey", "count": 5}, {"label": "Market source", "count": 5}, {"label": "timothysykes.com", "count": 2}, {"label": "www.marketscreener.com", "count": 2}, {"label": "MarketBeat", "count": 1}, {"label": "Simply Wall St.", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 45}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 16}, {"label": "Earnings", "count": 15}, {"label": "Analyst action", "count": 6}, {"label": "Guidance", "count": 4}, {"label": "Balance sheet", "count": 2}, {"label": "Macro sensitivity", "count": 1}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "61/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "72/100 classification confidence."}, {"label": "Company focus", "value": "45", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-2.6% over one week, +42.2% over four weeks, trend active, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Biodesix Inc. (BDSX) Stock Price | Live Quotes & Charts | NASDAQ"}], "updated_at": "2026-07-17T06:16:00.817722+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}